Treatment And Inhibition Of Inflammatory Lung Diseases In Patients Having Risk Alleles In The Genes Encoding IL33 And IL1RL1
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsShannon Bruse, Shane McCarthy, Aris Baras, Frederick Dewey, Omri Gottesman
Life of this patent
Estimating the term…
Abstract
IL33 antagonists alone or in combination with IL-4R antagonists can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in a subject having one or more risk alleles in the intronic IL1RL1 variant rs1420101, in the IL33 variant rs1342326, in both, or in variants in linkage disequilibrium thereof.
Claims30
1-12. (canceled)
A method for treating or inhibiting eosinophilic asthma, the method comprising administering an IL33 antagonist or a combination of an IL33 antagonist and an IL-4R antagonist to a subject having:
- i) the IL33 variant rs1342326 but not the intronic IL1RL1 variant rs1420101;
- or ii) both the intronic IL1RL1 variant rs1420101 (SEQ ID NO:
- 357) and the IL33 variant rs1342326, wherein the eosinophilic asthma is treated or inhibited in the subject.
14-27. (canceled)
A method for treating or inhibiting allergic rhinitis, the method comprising administering an IL33 antagonist or a combination of an IL33 antagonist and an IL-4R antagonist to a subject having:
- i) the IL33 variant rs1342326 but not the intronic IL1RL1 variant rs1420101;
- or ii) both the intronic IL1RL1 variant rs1420101 and the IL33 variant rs1342326, wherein allergic rhinitis is treated or inhibited in the subject.
30-32. (canceled)
34-36. (canceled)
The method according to 28, wherein the IL-4R antagonist comprises an antibody, or antigen-binding fragment thereof, that specifically binds to IL-4R.
A method for treating or inhibiting eosinophilic asthma-Chronic Obstructive Pulmonary Disease (COPD) overlap syndrome (ACOS), the method comprising administering an IL33 antagonist or a combination of an IL33 antagonist and an IL-4R antagonist to a subject having:
- i) the IL33 variant rs1342326 but not the intronic IL1RL1 variant rs1420101;
- or ii) both the intronic IL1RL1 variant rs1420101 and the IL33 variant rs1342326 rs1342326, wherein the eosinophilic COPD is treated or inhibited in the subject.
44-59. (canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.